title: Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study.
abstract: BACKGROUND
  We examined the association and interaction between maternal viral load and antibodies in vertical transmission of HIV in a non-randomized prospective study of 43 HIV-1 infected pregnant women who attended the San Juan City Hospital, Puerto Rico, and their 45 newborn infants. The women and infants received antiretroviral therapy.
  
  
  METHODS
  A nested PCR assay of the HIV-1 envelope V3 region and infant PBMC culture were performed to determine HIV status of the infants. Maternal and infant plasma were tested for HIV neutralization or enhancement in monocyte-derived macrophages.
  
  
  RESULTS
  Twelve (26.7%) infants were positive by the HIV V3 PCR assay and 3 of the 12 were also positive by culture. There was a trend of agreement between high maternal viral load and HIV transmission by multivariate analysis (OR = 2.5, CI = 0.92, p = 0.0681). Both maternal and infant plasma significantly (p = 0.001 for both) reduced HIV replication at 10(-1) dilution compared with HIV negative plasma. Infant plasma neutralized HIV (p = 0.001) at 10(-2) dilution but maternal plasma lost neutralizing effect at this dilution. At 10(-3) dilution both maternal and infant plasma increased virus replication above that obtained with HIV negative plasma but only the increase by maternal plasma was statistically significant (p = 0.005). There were good agreements in enhancing activity in plasma between mother-infant pairs, but there was no significant association between HIV enhancement by maternal plasma and vertical transmission.
  
  
  CONCLUSIONS
  Although not statistically significant, the trend of association between maternal viral load and maternal-infant transmission of HIV supports the finding that viral load is a predictor of maternal-infant transmission. Both maternal and infant plasma neutralized HIV at low dilution and enhanced virus replication at high dilution. The antiretroviral treatments that the women received and the small sample size may have contributed to the lack of association between HIV enhancement by maternal plasma and vertical transmission.
authors.affiliation: Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 35294-0022, USA. PaulKamara@westat.com
authors.forename: Paul
authors.initials: P
authors.lastname: Kamara
authors.forename: Loyda
authors.initials: L
authors.lastname: Melendez-Guerrero
authors.forename: Miguel
authors.initials: M
authors.lastname: Arroyo
authors.forename: Heidi
authors.initials: H
authors.lastname: Weiss
authors.forename: Pauline
authors.initials: P
authors.lastname: Jolly
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000956:Antigens, Viral / Q000097:blood; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000635:transmission* / Q000821:virology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D015999:Multivariate Analysis; D009500:Neutralization Tests; D016017:Odds Ratio; D011247:Pregnancy; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D000956:Antigens, Viral; D015483:HIV Antibodies
references.citation: Cell Mol Biol (Noisy-le-grand). 1997 Nov;43(7):1057-65
references.pmid: 9449539
references.citation: Lancet. 1994 Apr 23;343(8904):1001-5
references.pmid: 7909048
references.citation: MMWR Morb Mortal Wkly Rep. 1998 Mar 6;47(8):151-4
references.pmid: 9518278
references.citation: AIDS Res Hum Retroviruses. 1998 Apr 10;14(6):475-81
references.pmid: 9566549
references.citation: J Infect Dis. 1998 Jun;177(6):1737-41
references.pmid: 9607861
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):126-35
references.pmid: 9637577
references.citation: Am J Reprod Immunol. 1998 Jun;39(6):381-6
references.pmid: 9645269
references.citation: J Infect Dis. 1999 Mar;179(3):590-9
references.pmid: 9952365
references.citation: J Med Virol. 1999 May;58(1):59-62
references.pmid: 10223547
references.citation: N Engl J Med. 1999 Aug 5;341(6):394-402
references.pmid: 10432324
references.citation: Cell Mol Biol (Noisy-le-grand). 1999 Jun;45(4):423-31
references.pmid: 10432189
references.citation: Lancet. 1999 Sep 4;354(9181):795-802
references.pmid: 10485720
references.citation: J Virol. 1990 Apr;64(4):1437-40
references.pmid: 2319642
references.citation: Proc Natl Acad Sci U S A. 1990 May;87(9):3445-9
references.pmid: 2333294
references.citation: Ann Intern Med. 1991 Jan 15;114(2):119-27
references.pmid: 1984386
references.citation: Science. 1992 Feb 28;255(5048):1134-7
references.pmid: 1546316
references.citation: J Clin Invest. 1992 Jun;89(6):1923-30
references.pmid: 1601999
references.citation: MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
references.pmid: 1361652
references.citation: J Clin Immunol. 1992 Nov;12(6):429-39
references.pmid: 1287035
references.citation: Virology. 2000 Jul 20;273(1):52-9
references.pmid: 10891407
references.citation: J Infect Dis. 2001 Feb 15;183(4):539-45
references.pmid: 11170978
references.citation: Cell Mol Biol (Noisy-le-grand). 2001;47 Online Pub:OL39-47
references.pmid: 11936872
references.citation: Science. 1988 Jan 29;239(4839):476-81
references.pmid: 3277268
references.citation: Lancet. 1988 Apr 9;1(8589):790-4
references.pmid: 2895317
references.citation: Science. 1988 Oct 28;242(4878):580-3
references.pmid: 2972065
references.citation: Proc Natl Acad Sci U S A. 1989 Oct;86(20):8055-8
references.pmid: 2479014
references.citation: J Virol. 1990 Mar;64(3):1407-9
references.pmid: 2154621
references.citation: AIDS. 1993 Nov;7 Suppl 2:S45-8
references.pmid: 8161445
references.citation: J Acquir Immune Defic Syndr. 1994 Jun;7(6):617-22
references.pmid: 7513762
references.citation: Lancet. 1994 May 28;343(8909):1364
references.pmid: 7910354
references.citation: Clin Exp Immunol. 1994 Jun;96(3):389-94
references.pmid: 8004808
references.citation: J Virol. 1994 Oct;68(10):6684-9
references.pmid: 7521920
references.citation: N Engl J Med. 1994 Nov 3;331(18):1173-80
references.pmid: 7935654
references.citation: J Clin Invest. 1995 Feb;95(2):732-7
references.pmid: 7860754
references.citation: J Virol. 1996 Jan;70(1):427-44
references.pmid: 8523556
references.citation: Am J Epidemiol. 1995 Dec 15;142(12):1330-7
references.pmid: 7503054
references.citation: Clin Exp Immunol. 1995 Dec;102(3):476-80
references.pmid: 8536360
references.citation: J Infect Dis. 1996 Jan;173(1):60-7
references.pmid: 8537683
references.citation: JAMA. 1996 Feb 28;275(8):599-605
references.pmid: 8594240
references.citation: N Engl J Med. 1996 Nov 28;335(22):1621-9
references.pmid: 8965861
references.citation: J Infect Dis. 1997 Jan;175(1):172-5
references.pmid: 8985214
references.citation: AIDS. 1997 Jul;11(8):1056-8
references.pmid: 9223743
references.citation: J Infect Dis. 1993 Jul;168(1):207-10
references.pmid: 8515110
references.citation: J Acquir Immune Defic Syndr. 1994 Jan;7(1):63-7
references.pmid: 8263755
references.citation: J Acquir Immune Defic Syndr. 1994 Mar;7(3):261-4
references.pmid: 7906303
references.citation: J Med Virol. 1998 Feb;54(2):113-7
references.pmid: 9496369